308 related articles for article (PubMed ID: 29621903)
1. Impact of Nrf2 on tumour growth and drug sensitivity in oncogenic K-ras-transformed cells in vitro and in vivo.
Shao J; Glorieux C; Liao J; Chen P; Lu W; Liang Z; Wen S; Hu Y; Huang P
Free Radic Res; 2018 Jun; 52(6):661-671. PubMed ID: 29621903
[TBL] [Abstract][Full Text] [Related]
2. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
DeNicola GM; Karreth FA; Humpton TJ; Gopinathan A; Wei C; Frese K; Mangal D; Yu KH; Yeo CJ; Calhoun ES; Scrimieri F; Winter JM; Hruban RH; Iacobuzio-Donahue C; Kern SE; Blair IA; Tuveson DA
Nature; 2011 Jul; 475(7354):106-9. PubMed ID: 21734707
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
4. Continuous activation of Nrf2 and its target antioxidant enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial cells.
Yang X; Wang D; Ma Y; Xu X; Zhu Z; Wang X; Deng H; Li C; Chen M; Tong J; Yamanaka K; An Y
Toxicol Appl Pharmacol; 2015 Dec; 289(2):231-9. PubMed ID: 26420645
[TBL] [Abstract][Full Text] [Related]
5. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer.
Baird L; Yamamoto M
Mol Cell Biol; 2021 Jan; 41(2):. PubMed ID: 33139492
[TBL] [Abstract][Full Text] [Related]
6. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.
Li PC; Tu MJ; Ho PY; Jilek JL; Duan Z; Zhang QY; Yu AX; Yu AM
Drug Metab Dispos; 2018 Jan; 46(1):2-10. PubMed ID: 29061583
[TBL] [Abstract][Full Text] [Related]
7. InĀ vivo imaging of antioxidant response element activity during liver regeneration after partial hepatectomy.
Alizai PH; Bertram L; Fragoulis A; Wruck CJ; Kroy DC; Klinge U; Neumann UP; Schmeding M
J Surg Res; 2016 Dec; 206(2):525-535. PubMed ID: 27884351
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.
Ning S; Sekar TV; Scicinski J; Oronsky B; Peehl DM; Knox SJ; Paulmurugan R
Oncotarget; 2015 Aug; 6(25):21547-56. PubMed ID: 26280276
[TBL] [Abstract][Full Text] [Related]
9. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
10. Butylated hydroxyanisole induces distinct expression patterns of Nrf2 and detoxification enzymes in the liver and small intestine of C57BL/6 mice.
Luo L; Chen Y; Wu D; Shou J; Wang S; Ye J; Tang X; Wang XJ
Toxicol Appl Pharmacol; 2015 Nov; 288(3):339-48. PubMed ID: 26291391
[TBL] [Abstract][Full Text] [Related]
11. PM2.5 induces Nrf2-mediated defense mechanisms against oxidative stress by activating PIK3/AKT signaling pathway in human lung alveolar epithelial A549 cells.
Deng X; Rui W; Zhang F; Ding W
Cell Biol Toxicol; 2013 Jun; 29(3):143-57. PubMed ID: 23525690
[TBL] [Abstract][Full Text] [Related]
12. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
Chian S; Thapa R; Chi Z; Wang XJ; Tang X
Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
[TBL] [Abstract][Full Text] [Related]
13.
Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
[TBL] [Abstract][Full Text] [Related]
14. Nrf2/ARE pathway activation, HO-1 and NQO1 induction by polychlorinated biphenyl quinone is associated with reactive oxygen species and PI3K/AKT signaling.
Li L; Dong H; Song E; Xu X; Liu L; Song Y
Chem Biol Interact; 2014 Feb; 209():56-67. PubMed ID: 24361488
[TBL] [Abstract][Full Text] [Related]
15. Regulatory role of KEAP1 and NRF2 in PPARĪ³ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
16. 4-Hydroxyestradiol induces mammary epithelial cell transformation through Nrf2-mediated heme oxygenase-1 overexpression.
Park SA; Lee MH; Na HK; Surh YJ
Oncotarget; 2017 Jan; 8(1):164-178. PubMed ID: 27438141
[TBL] [Abstract][Full Text] [Related]
17. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease.
Son HJ; Han SH; Lee JA; Shin EJ; Hwang O
Free Radic Res; 2017 Jun; 51(6):633-645. PubMed ID: 28770670
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with Ras/Forkhead box M1 signaling pathway.
Park YH; Kim SU; Kwon TH; Kim JM; Song IS; Shin HJ; Lee BK; Bang DH; Lee SJ; Lee DS; Chang KT; Kim BY; Yu DY
Oncogene; 2016 Jul; 35(27):3503-13. PubMed ID: 26500057
[TBL] [Abstract][Full Text] [Related]
19. Dimethylfumarate attenuates restenosis after acute vascular injury by cell-specific and Nrf2-dependent mechanisms.
Oh CJ; Park S; Kim JY; Kim HJ; Jeoung NH; Choi YK; Go Y; Park KG; Lee IK
Redox Biol; 2014; 2():855-64. PubMed ID: 25009787
[TBL] [Abstract][Full Text] [Related]
20. Brg1-mediated Nrf2/HO-1 pathway activation alleviates hepatic ischemia-reperfusion injury.
Ge M; Yao W; Yuan D; Zhou S; Chen X; Zhang Y; Li H; Xia Z; Hei Z
Cell Death Dis; 2017 Jun; 8(6):e2841. PubMed ID: 28569786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
